On October 22, 2026 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, reported that company management will participate in two upcoming investor conferences in November.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the events are as follows:
Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA
Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET
Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK
Members of management will be available for 1×1 meetings on Thursday, November 19, 2026
The live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.
(Press release, Adicet Bio, OCT 22, 2026, View Source [SID1234673676])